Nicolas van Baren

7.7k citations

54 papers · 4.9k indexed · 2 hit papers · h-index 32

Co-authors: Pierre G. Coulie Thierry Boon Jean‐François Baurain Benoı̂t J. Van den Eynde Bernard Lethé Ivan Théate Charles De Smet Frédéric Lehmann
Topics: Immunotherapy and Immune Responses (32 papers)T-cell and B-cell Immunology (20 papers)vaccines and immunoinformatics approaches (14 papers)
Cited by: Biological Psychiatry Immunology Oncology
Journals: Proceedings of the National Academy of Sciences Nature Communications The Journal of Experimental Medicine
Partner nations: Belgium France United Kingdom

In The Last Decade

Nicolas van Baren

53 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor

1997 639 citations Hideyuki Ikeda, Bernard Lethé et al. Immunity profile →

Peers

Countries citing papers authored by Nicolas van Baren

Since Specialization

Citations

This map shows the geographic impact of Nicolas van Baren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas van Baren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas van Baren more than expected).

Fields of papers citing papers by Nicolas van Baren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas van Baren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas van Baren. The network helps show where Nicolas van Baren may publish in the future.

Co-authorship network of co-authors of Nicolas van Baren

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas van Baren. A scholar is included among the top collaborators of Nicolas van Baren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas van Baren. Nicolas van Baren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	GARP-expressing Tregs as a source of immunosuppressive TGF-β1 in human tumors 2025 ·Cancer Immunology Immunotherapy ·(unknown),(unknown),(unknown),(unknown),Étienne Marbaix,Frank Aboubakar Nana,Marc Van den Eynde,(unknown),Javier Carrasco,Agnès Noël,Nicolas van Baren,Sophie Lucas	0
2	Spatial Distribution of Non-Immune Cells Expressing Glycoprotein A Repetitions Predominant in Human and Murine Metastatic Lymph Nodes 2023 ·Cancers ·(unknown),(unknown),(unknown),(unknown),(unknown),Silvia Blacher,Nicolas van Baren,Frédéric Kridelka,Sophie Lucas,Agnès Noël	2
3	Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer 2020 ·Nature Communications ·(unknown),(unknown),(unknown),Stéphanie Liénart,Orian Bricard,(unknown),(unknown),(unknown),Gitte De Boeck,(unknown),Inge Van de Walle,Bas van der Woning,Michael Saunders,Hans de Haard,(unknown),Wim Maes,Hans Deckmyn,Pierre G. Coulie,Nicolas van Baren,Sophie Lucas	104
4	Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers 2019 ·Cancer Immunology Research ·(unknown),(unknown),Vincent Stroobant,Caroline Bouzin,(unknown),(unknown),(unknown),(unknown),Jean‐Christophe Renauld,Nicolas van Baren,(unknown),Étienne Marbaix,Benoı̂t J. Van den Eynde	45
5	Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma 2016 ·Journal of Clinical Oncology ·Sofie Wilgenhof,Jurgen Corthals,Carlo Heirman,Nicolas van Baren,Sophie Lucas,Pia Kvistborg,Kris Thielemans,Bart Neyns	240
6	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients 2016 ·Journal of Translational Medicine ·Teofila Seremet,Alexander Koch,Yanina Jansen,Max Schreuer,Sofie Wilgenhof,V. del Mármol,Danielle Líénard,Kris Thielemans,(unknown),Mark Kockx,Wim Van Criekinge,Pierre G. Coulie,Tim De Meyer,Nicolas van Baren,Bart Neyns	24
7	Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance 2015 ·OncoImmunology ·Nathalie Vigneron,Nicolas van Baren,Benoı̂t J. Van den Eynde	20
8	Tryptophan-Degrading Enzymes in Tumoral Immune Resistance 2015 ·Frontiers in Immunology ·Nicolas van Baren,(unknown)	192
9	Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues 2014 ·Cancer Immunology Research ·Ivan Théate,Nicolas van Baren,Luc Pilotte,Pierre Moulin,Pierre Larrieu,Jean‐Christophe Renauld,Caroline Hervé,Ilse Gutierrez-Roelens,Étienne Marbaix,Christine Sempoux,Benoı̂t J. Van den Eynde	284
10	Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapybreakdown → 2013 ·Cancer Discovery ·Hubing Shi,Willy Hugo,Xiangju Kong,Aayoung Hong,Richard C. Koya,Gatien Moriceau,Thinle Chodon,Rongqing Guo,Douglas B. Johnson,Kimberly B. Dahlman,Mark C. Kelley,Richard Kefford,Bartosz Chmielowski,John A. Glaspy,Jeffrey A. Sosman,Nicolas van Baren,Georgina V. Long,Antoni Ribas,Roger S. Lo	715
11	Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases 2012 ·Cancer Research ·Arcadi Cipponi,Marjorie Mercier,Teofila Seremet,Jean‐François Baurain,Ivan Théate,Joost van den Oord,Marguerite Stas,Thierry Boon,Pierre G. Coulie,Nicolas van Baren	204
12	Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases 2011 ·Cancer Research ·Véronique Corbière,Jacques Chapiro,Vincent Stroobant,Wenbin Ma,Christophe Lurquin,Bernard Lethé,Nicolas van Baren,Benoı̂t J. Van den Eynde,Thierry Boon,Pierre G. Coulie	142
13	Hemorrhagic regression of melanoma metastases during therapeutic vaccination: a report of three cases 2009 ·Melanoma Research ·(unknown),Nicolas van Baren,Aude Bonehill,Jurgen Corthals,An M. T. Van Nuffel,Carlo Heirman,Truus Roelandt,Arlette De Coninck,Ivan Van Riet,(unknown),Annieta Goossens,Guy Verfaillie,Diane Roseeuw,Kris Thielemans,Bart Neyns	3
14	Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells 2007 ·Molecular Cancer ·Gaëlle Tilman,(unknown),Francis Brasseur,Nicolas van Baren,Anabelle Decottignies	99
15	Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus 2003 ·The Journal of Immunology ·Vaios Karanikas,Christophe Lurquin,Didier Colau,Nicolas van Baren,Charles De Smet,Bernard Lethé,Thierry Connerotte,Véronique Corbière,Marie‐Ange Demoitié,Danielle Líénard,Brigitte Dréno,Thierry Velu,Thierry Boon,Pierre G. Coulie	88
16	A gene expressed exclusively in acute B lymphoblastic leukemias 2003 ·Genomics ·(unknown),(unknown),Etienne De Plaen,Edgar Jost,Sophie Dupont,Geneviève Ameye,Lucienne Michaux,Pierre G. Coulie,Daniel Olive,Thierry Boon,Nicolas van Baren	3
17	MAGE-A genes are not expressed in human leukemias 2001 ·Leukemia ·Hérvè Chambost,Nicolas van Baren,F. Brasseur,Daniel Olive	21
18	High Frequency of Autologous Anti-Melanoma CTL Directed Against an Antigen Generated by a Point Mutation in a New Helicase Gene 2000 ·The Journal of Immunology ·Jean‐François Baurain,Didier Colau,Nicolas van Baren,Claire Landry,(unknown),Miikka Vikkula,Thierry Boon,Pierre G. Coulie	83
19	Mutations of the β₂‐microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides 1998 ·Tissue Antigens ·Ricardo Benítez Benítez,D. Godelaine,Miguel Ángel López‐Nevot,F Brasseur,(unknown),M. Marchand,Maria R. Oliva,Nicolas van Baren,Teresa Cabrera,Guy Andry,Claire Landry,Francisco Ruiz‐Cabello,Thierry Boon,Federico Garrido	118
20	Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptorbreakdown → 1997 ·Immunity ·Hideyuki Ikeda,Bernard Lethé,Frédéric Lehmann,Nicolas van Baren,Jean‐François Baurain,Charles De Smet,Hérvè Chambost,Massimo Vitale,Alessandro Moretta,Thierry Boon,Pierre G. Coulie	639

About Nicolas van Baren

Nicolas van Baren is a scholar working on Biological Psychiatry, Immunology and Oncology, having authored 54 papers that have together received 4.9k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (32 papers), T-cell and B-cell Immunology (20 papers) and vaccines and immunoinformatics approaches (14 papers). The work is most often cited by research in Biological Psychiatry (470 citations), Immunology (2.9k citations) and Oncology (2.3k citations). Nicolas van Baren has collaborated with scholars based in Belgium, France and United Kingdom. Frequent co-authors include Pierre G. Coulie, Thierry Boon, Jean‐François Baurain, Benoı̂t J. Van den Eynde, Bernard Lethé, Ivan Théate, Charles De Smet, Frédéric Lehmann, Christophe Lurquin and Hérvè Chambost. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nature Communications and The Journal of Experimental Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact